Generated by AI
Artelo Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing proprietary therapeutics that modulate lipid-signaling pathways. Artelo Biosciences concentrates on treatments for conditions with significant unmet medical needs, including cancer-related anorexia, pain, inflammation, anxiety, dermatologic disorders, and other serious diseases. Its current pipeline includes product candidates such as ART27.13, ART12.11, and ART26.12, which are being developed across multiple therapeutic areas with an emphasis on endocannabinoid and fatty acid binding protein biology. The company’s work centers on advancing novel small-molecule and cannabinoid-based approaches aimed at improving care in oncology, neurology, and related fields. Artelo Biosciences is headquartered in Solana Beach, California, and operates as a research-driven company within the broader pharmaceutical market.
Website505 Lomas Santa Fe
Solana Beach, CA, 92075
United States
The latest articles about ARTL.
Summary of Sep 24's posts. Generated by AI.
Summary of Sep 23's posts. Generated by AI.
Artelo Biosciences, Inc. (NASDAQ: ARTL) shares are surging Wednesday afternoon after the clinical-stage biopharmaceutical company announced the filing of a new provisional patent application covering its drug candidate ART27.13 for the treatment of obesity.
Summary of Sep 24's posts. Generated by AI.
Investors talking about ARTL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.